A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Conditions: Choroidal Neovascularization Secondary to Pathologic Myopia Interventions: Drug: Faricimab; Drug: Ranibizumab; Procedure: Sham Procedure Sponsors: Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials